Immunotherapy shows promise in reducing recurrence rates for high-risk skin cancer, despite mixed results in recent clinical ...

Non-small cell lung cancer (NSCLC) develops in lung tissues, but when it's metastatic, it has spread to distant areas of the ...

Panelists discuss how the PODIUM-303 study demonstrated improved progression-free survival (9.3 vs 7.4 months) and response rates (56% vs 44%) when adding retifanlimab to carboplatin-paclitaxel in ...

Non-Small Cell Lung Cancer Market grows as immunotherapy approvals by Merck & Bristol-Myers reshape global treatment pathways. Anurag Tiwari Orion Market Research Pvt Ltd +91 91798 28694 email us here ...

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have improved survival following immunotherapy compared to patients without ...

Lung cancer can be hereditary, with mutations in the EGFR and KRAS genes potentially playing a role. Smoking, however, is by far the biggest risk factor.

Survival for non-small-cell lung cancer (NSCLC) remains unacceptably low, even in stage IA–IIA. Current guidelines recommend adjuvant treatment for patients considered to be at high risk in stages IB ...

Researchers studied the relationship between lymphovascular invasion and adverse outcomes in patients with cutaneous squamous cell carcinoma.

Objectives Penpulimab is a novel programmed death-1 (PD-1) inhibitor that has been approved in China for use in combination with chemotherapy as a first-line treatment for locally advanced or ...

Jain: Hi, thanks for having me. I'm Dr. Prantesh Jain, a thoracic oncologist at Roswell Park Cancer Center, and I'm excited to be here to share updates in lung cancer from ASCO this year. Sabari: ...

Locally advanced (generally stage 3) head and neck squamous cell carcinoma is cancer that has grown outside its original location but has not yet spread to distant sites. It can be challenging to ...